Early-phase lymphoma trial testing a new targeted immune treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests SIRPant-M, a new immune-based treatment, in adults with lymphoma that has come back or not responded to earlier care. It may help by shrinking lymphoma using either the drug alone or the drug plus a targeted radiation treatment for certain lymphoma types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign informed consent.
- Your lymphoma is non-Hodgkin lymphoma (NHL) that has relapsed or is refractory, and you’ve already had at least two kinds of whole-body cancer treatment.
- You have at least one safe-to-treat lesion (lymph node or skin/subcutaneous spot) between 1.5 and 5 cm in one direction, and it has not been previously treated with radiation.
- Your blood counts, kidney, and liver tests are high enough for treatment, and your overall health is limited no more than “ECOG 2” (can do some daily activities).
- Your heart function is acceptable (AHA class 1), you have a life expectancy of more than 3 months, and you are not currently pregnant.
- You can have required biopsies and clinic visits for the study, and you meet other key safety checks (no major uncontrolled illnesses or active serious infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called ARC-02 for people with certain types of B-cell non-Hodgkin lymphoma (a cancer of the immune system) that has not responded well enough to at least two prior treatments. The goal is to see if this drug can help when other options are no longer working.
This trial tests a new drug, SB-4826, for people with advanced solid tumors or certain types of lymphoma that have not responded to standard treatments. The goal is to see if the drug is safe and effective, either alone or with another drug called rituximab.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests an experimental drug, SP-3164, for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to prior treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a new targeted therapy (linperlisib) combined with rituximab, an existing antibody drug, for people with a slow-growing type of non-Hodgkin lymphoma that has come back or not responded to previous treatments. The goal is to see if this combination is safe and effective in controlling the cancer.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
Hear when a new Refractory Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.